retatrutide peptides (RETA) – Research Peptide Retatrutide Triple Agonist (GLP-1/GIP/GCG) |

Am J Med (2010) 123:468

It activates GLP-1 receptors, leading to increased insulin release from pancreatic beta cells in response to elevated blood sugar levels, making it an excellent treatment for type 2 diabetes

Adverse effects observed in trials include: Nausea and vomiting particularly during dose escalation Diarrhoea or constipation Decreased appetite Injection site reactions Fatigue and dizziness Gallbladder-related events (including gallstones), consistent with effects observed with other GLP-1based therapies [9] Rare cases of pancreatitis , a risk associated with the GLP-1 receptor agonist class [10] [3] Because retatrutide is not licensed in the UK, the MHRA has not issued specific prescribing or dosing guidance for this compound

The total weekly amount stays the same, but dividing it into two smaller injections reduces the spike in side effects that a single weekly dose can cause

J Diabetes Complicat